Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
Corrado Pelaia,Anna Ferrante Bannera,Fioramante Lello Rotundo,Francesco Giuseppe Tropea,Giuseppe Armentaro,Angelantonio Maglio,Angela Sciacqua,Alessandro Vatrella,Girolamo Pelaia
DOI: https://doi.org/10.2147/COPD.S407238
2023-05-26
International Journal of COPD
Abstract:Corrado Pelaia, 1 Anna Ferrante Bannera, 1 Fioramante Lello Rotundo, 1 Francesco Giuseppe Tropea, 1 Giuseppe Armentaro, 2 Angelantonio Maglio, 3 Angela Sciacqua, 2 Alessandro Vatrella, 3 Girolamo Pelaia 1 1 Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy; 2 Department of Medical and Surgical Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy; 3 Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy Correspondence: Corrado Pelaia, Campus Universitario "S. Venuta", Viale Europa – Località Germaneto, Catanzaro, 88100, Italy, Tel +39 0961 3647007, Fax +39 0961 3647193, Email Background: The pharmacological association umeclidinium/vilanterol (UMEC/VI) allows to implement a very effective dual bronchodilation in chronic obstructive pulmonary disease (COPD), thus optimizing bronchodilating therapy. Methods: The main purpose of our real-world observational study was to evaluate in COPD patients the effects of UMEC/VI on lung function and respiratory symptoms. Functional and clinical parameters were assessed at baseline, and after 52 weeks of treatment with this combined double inhaled therapy. Results: We enrolled 110 subjects suffering from COPD. A 12-month UMEC/VI treatment induced significant improvements in total lung capacity (TLC) (p < 0.05), and residual volume (RV) (p < 0.0001). Pulmonary deflation was paralleled by significant increases of forced expiratory volume in one second (FEV 1 ) (p < 0.0001), forced vital capacity (FVC) (p < 0.01), forced expiratory flow between 25% and 75% of FVC (FEF 25– 75 ) (p < 0.0001) and diffusion capacity of the lung (DLCOcSB) (p < 0.05). In addition, in the same period, we also observed significant reductions of airway resistance including total resistance (R tot ) (p < 0.0001) and specific effective resistance (sR eff ) (p < 0.0001). Other improvements were detected with regard to modified British Medical Research Council (mMRC) questionnaire score (p < 0.0001), COPD Assessment Test (CAT) score (p < 0.0001), and COPD exacerbation rate (p < 0.0001). In particular, the reported changes of mMRC/CAT scores and COPD exacerbation numbers were significantly correlated with UMEC/VI–induced modifications of TLC, RV, FVC and FEV 1 . Conclusion: In conclusion, our study corroborates in a real-life context the effectiveness of UMEC/VI in COPD treatment. Indeed, our broad investigational strategy has allowed to better characterize the functional mechanisms underpinning the therapeutic properties of UMEC/VI association. Keywords: COPD, dual inhaled therapy, lung function, airway resistance, exacerbations Chronic obstructive pulmonary disease (COPD) is a respiratory disorder usually characterized by the persistence and poor reversibility of airflow limitation, resulting from a pathological inflammatory response of the airways and lung parenchyma to the inhalation of cigarette smoke and/or other atmospheric pollutants. 1 COPD is very frequent, affecting 10% of people over the age of 45 years, and currently represents the third leading cause of death worldwide. 2–4 In particular, COPD is a heterogeneous syndrome including several phenotypes such as chronic obstructive bronchitis, small airway disease with peribronchiolar fibrosis and pulmonary emphysema, 5 the latter being featured by lung hyperinflation and destruction of alveolar walls. Pulmonary emphysema is often associated with the inflammatory changes shaping chronic bronchitis and small airway disease. 6 7,8 On the other hand, limitation of the expiratory flow compromises the emptying of intrapulmonary air, thus leading to air trapping at the alveolar level with consequent lung hyperinflation. 5 This pathophysiological factor is the main cause of COPD symptoms, such as dyspnea and decreased exercise tolerance. 6 Furthermore, the destruction of interalveolar septa that characterizes emphysema also leads to amputation of the pulmonary capillary bed, with a consequent reduction of gas exchange surface and alveolar-capillary diffusion. 7 The main goals of COPD treatment include relief of respiratory symptoms and prevention of exacerbations. 8 In order to pursue these therapeutic goals, the most important drugs are represented by inhaled bronchodilators, which include anticholinergics/antimuscarinics and β 2 -adrenergic agonists. 9 Regular and continuous therapies with long-acting β 2 -adrenergic receptor agonists (LABA) and long-acting muscarinic recept -Abstract Truncated-
respiratory system